1. Home
  2. CSQ vs HAE Comparison

CSQ vs HAE Comparison

Compare CSQ & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Strategic Total Return

CSQ

Calamos Strategic Total Return

HOLD

Current Price

$17.88

Market Cap

3.0B

Sector

Finance

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$59.71

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSQ
HAE
Founded
2003
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.8B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
CSQ
HAE
Price
$17.88
$59.71
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$85.38
AVG Volume (30 Days)
252.0K
649.1K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
7.53%
N/A
EPS Growth
N/A
44.54
EPS
N/A
2.46
Revenue
N/A
$910,373,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.46
P/E Ratio
N/A
$24.35
Revenue Growth
N/A
N/A
52 Week Low
$13.11
$47.32
52 Week High
$19.83
$87.32

Technical Indicators

Market Signals
Indicator
CSQ
HAE
Relative Strength Index (RSI) 32.14 34.86
Support Level $17.29 $48.47
Resistance Level $19.48 $66.86
Average True Range (ATR) 0.30 1.84
MACD -0.10 -0.04
Stochastic Oscillator 9.70 9.69

Price Performance

Historical Comparison
CSQ
HAE

About CSQ Calamos Strategic Total Return

Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: